Top

Published in:

01-11-2007

Peritumoral Inflammatory Infiltrate is not a Prognostic Factor in Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy

Authors: Rodrigo O. Perez, Angelita Habr-Gama, Rafael Miyashiro Nunes dos Santos, Igor Proscurshim, Fábio G. Campos, Viviane Rawet, Desiderio Kiss, Ivan Cecconello

Published in: Journal of Gastrointestinal Surgery | Issue 11/2007

Abstract

Background

Peritumoral inflammatory response has been considered a good prognostic factor for colorectal cancer. However, this has not been evaluated in patients submitted to neoadjuvant therapy for distal rectal cancer. For this reason, we decided to study the effect of the presence of this pathological finding on disease recurrence and survival.

Methods

The peritumoral inflammatory infiltrate from recovered pathological specimens of patients operated after neoadjuvant therapy for distal rectal cancer was graded (positive or negative). Patients were compared according to the presence of peritumoral inflammatory response.

Results

Of the 168 patients, 63 (37%) patients had a peritumoral inflammatory response. The lack of peritumoral inflammatory response was significantly associated with the presence of mucinous component (13 vs 3%; p = 0.02). Five-year overall survival (91 vs 81%) and disease-free survival (57 vs 48%) were not significantly different between patients with and without peritumoral inflammatory response (p = 0.5 and 0.3, respectively).

Conclusions

Peritumoral inflammatory response is not a favorable prognostic factor in patients with distal rectal cancer after neoadjuvant chemoradiation therapy. Possibly, the immunosuppressive action of chemoradiation therapy may lead to a loss of function of the immunological response, which may represent a disadvantage of the neoadjuvant approach for the management of distal rectal cancer.

Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638–646.PubMedCrossRef

Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320–2328.PubMedCrossRef

Espi A, Arenas J, Garcia-Granero E, Marti E, Lledo S. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Dis Colon Rectum 1996;39:429–434.PubMedCrossRef

Fisher ER, Paik SM, Rockette H, Jones J, Caplan R, Fisher B. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Human Pathol 1989;20:159–163.CrossRef

Higgins CA, Hatton WJ, McKerr G, Harvey D, Carson J, Hannigan BM. Macrophages and apoptotic cells in human colorectal tumours. Biologicals 1996;24:329–332.PubMedCrossRef

Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M. Mast cells in colorectal neoplasias and premalignant disorders. Dis Colon Rectum 1995;38:290–293.PubMedCrossRef

Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999;189:487–495.PubMedCrossRef

Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318–324.PubMedCrossRef

Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M. Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol 1995;34:69–73.PubMed

10.

Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;1:1303–1306.PubMedCrossRef

11.

Habr-Gama A, Perez RO, Kiss DR, Rawet V, Scanavini A, Santinho PM, Nadalin W. Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepatogastroenterology 2004;51:1703–1707.PubMed

12.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–1740.PubMedCrossRef

13.

Tjandra JJ, Kilkenny JW, Buie WD, Hyman N, Simmang C, Anthony T, Orsay C, Church J, Otchy D, Cohen J, Place R, Denstman F, Rakinic J, Moore R, Whiteford M. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 2005;48:411–423.PubMedCrossRef

14.

Anthony T, Simmang C, Hyman N, Buie D, Kim D, Cataldo P, Orsay C, Church J, Otchy D, Cohen J, Perry WB, Dunn G, Rafferty J, Ellis CN, Rakinic J, Fleshner P, Stahl T, Gregorcyk S, Ternent C, Kilkenny JW, 3rd, Whiteford M. Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Dis Colon Rectum 2004;47:807–817.PubMedCrossRef

15.

Buie WD, MacLean AR, Attard JA, Brasher PM, Chan AK. Neoadjuvant chemoradiation increases the risk of pelvic sepsis after radical excision of rectal cancer. Dis Colon Rectum 2005;48:1868–1874.PubMedCrossRef

16.

Dahlberg M, Glimelius B, Graf W, Pahlman L. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 1998;41:543–549 (discussion 549–551).PubMedCrossRef

17.

Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 1996;78:968–976.PubMedCrossRef

18.

Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990;211:187–195.PubMedCrossRef

19.

Rau B, Wust P, Riess H, Schlag PM. [Preoperative radiochemotherapy of rectal carcinoma. Current status]. Zentralbl Chir 2000;125:356–364.PubMed

20.

Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silva e Sousa AH, Jr., Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240:711–717 (discussion 717–718).PubMed

21.

Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, Gama-Rodrigues J. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006;10:1319–1328 (discussion 1328–1329).PubMedCrossRef

22.

Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1–27.PubMed

23.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–998.PubMedCrossRef

24.

Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293–299.PubMedCrossRef

25.

Weiss RA. Viruses, cancer and AIDS. FEMS Immunol Med Microbiol 1999;26:227–232.PubMedCrossRef

26.

Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Safety 2000;23:101–113.PubMedCrossRef

27.

De Quay N, Cerottini JP, Albe X, Saraga E, Givel JC, Caplin S. Prognosis in Duke’s B colorectal carcinoma: the Jass classification revisited. Eur J Surg 1999;165:588–592.PubMedCrossRef

28.

Jass JR, Cottier DS, Jeevaratnam P, Pokos V, Holdaway KM, Bowden ML, Van de Water NS, Browett PJ. Diagnostic use of microsatellite instability in hereditary non-polyposis colorectal cancer. Lancet 1995;346:1200–1201.PubMedCrossRef

29.

Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macri E, Fornasarig M, Boiocchi M. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999;154:1805–1813.PubMed

30.

Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, Walsh MD, Simms LA, Biden KG, Young JP, Leggett BA, Jass JR, Radford-Smith GL. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001;48:360–366.PubMedCrossRef

31.

Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, Kawakami Y. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 2003;63:5564–5572.PubMed

32.

Habr-Gama A, de Souza PM, Ribeiro U, Jr., Nadalin W, Gansl R, Sousa AH, Jr., Campos FG, Gama-Rodrigues J. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41:1087–1096.PubMedCrossRef

33.

Bullard KM, Trudel JL, Baxter NN, Rothenberger DA. Primary perineal wound closure after preoperative radiotherapy and abdominoperineal resection has a high incidence of wound failure. Dis Colon Rectum 2005;48:438–443.PubMedCrossRef

34.

Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005;23:8697–8705.PubMedCrossRef

35.

Wichmann MW, Meyer G, Adam M, Hochtlen-Vollmar W, Angele MK, Schalhorn A, Wilkowski R, Muller C, Schildberg FW. Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. Dis Colon Rectum 2003;46:875–887.CrossRef

36.

Tartter PI, Martinelli G, Steinberg B, Barron D. Changes in peripheral T-cell subsets and natural-killer cytotoxicity in relation to colorectal cancer surgery. Cancer Detect Prev 1986;9:359–364.PubMed

37.

Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987;122:1264–1268.PubMed

38.

Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, Molteni C, Trabattoni D, Fossati S, Clerici M, Galli M, Moroni M, Franzetti F, Gori A. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002;186:606–616.PubMedCrossRef

39.

Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 2001;1:7.PubMedCrossRef

40.

Papadopoulos VN, Michalopoulos A, Netta S, Basdanis G, Paramythiotis D, Zatagias A, Berovalis P, Harlaftis N. Prognostic significance of mucinous component in colorectal carcinoma. Techn Coloproctol 2004;8(Suppl 1):s123–s125.CrossRef

41.

Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47–56.PubMedCrossRef

42.

Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.PubMedCrossRef

43.

Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427–437.PubMedCrossRef

44.

Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.PubMedCrossRef

Title: Peritumoral Inflammatory Infiltrate is not a Prognostic Factor in Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy
Authors: Rodrigo O. Perez
Angelita Habr-Gama
Rafael Miyashiro Nunes dos Santos
Igor Proscurshim
Fábio G. Campos
Viviane Rawet
Desiderio Kiss
Ivan Cecconello
Publication date: 01-11-2007
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 11/2007
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-007-0287-8

At a glance: The STEP trials

Springer Medicine

Peritumoral Inflammatory Infiltrate is not a Prognostic Factor in Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2007

Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis

Clinical Impact of Lymphadenectomy Extent in Resectable Esophageal Cancer

Prospective Evaluation and 7-Year Follow-up of Swedish Adjustable Gastric Banding in Adults with Extreme Obesity

A Composite Adenoendocrine Carcinoma of the Stomach Arising from a Neuroendocrine Tumor

Can Surgeons Think and Operate with Haptics at the Same Time?

Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer